gossylic nitrile-1,1'-diacetate: inhibits human immunodeficiency virus Type I replication; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 122660 |
| CHEMBL ID | 51778 |
| MeSH ID | M0199698 |
| Synonym |
|---|
| gossylic nitrile-1,1'-diacetate |
| [2-(1-acetoxy-8-cyano-6,7-dihydroxy-5-isopropyl-3-methyl-2-naphthyl)-8-cyano-6,7-dihydroxy-5-isopropyl-3-methyl-1-naphthyl] acetate |
| 94242-60-1 |
| 6,6',7,7'-tetrahydroxy-3,3'-dimethyl-2,2'-diacetoxy-5,5'-bis(1-methylethyl)-[2,2'-binaphthalene]-, 8,8'-dicarbonitrile |
| CHEMBL51778 , |
| (2,2'-binaphthalene)-8,8'-dicarbonitrile, 1,1'-bis(acetyloxy)-6,6',7,7'-tetrahydroxy-3,3'-dimethyl-5,5'-bis(1-methylethyl)- |
| acetic acid 1''-acetoxy-8,8''-dicyano-6,7,6'',7''-tetrahydroxy-5,5''-diisopropyl-3,3''-dimethyl-[2,2'']binaphthalenyl-1-yl ester |
| bdbm50010438 |
| gn-1,1-da |
| DTXSID50241224 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| L-lactate dehydrogenase A chain | Homo sapiens (human) | Ki | 2.0000 | 0.0500 | 3.7650 | 8.5000 | AID1276043 |
| L-lactate dehydrogenase B chain | Homo sapiens (human) | Ki | 33.0000 | 0.0500 | 0.7700 | 1.4000 | AID1276044 |
| Aldo-keto reductase family 1 member B1 | Homo sapiens (human) | Ki | 7.3000 | 0.0190 | 3.4193 | 9.3000 | AID220721 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID159611 | Antimalarial activity against chloroquine-resistant Plasmodium falciparum FCB/NC1 | 1986 | Journal of medicinal chemistry, Sep, Volume: 29, Issue:9 | Biologically active derivatives of gossypol: synthesis and antimalarial activities of peri-acylated gossylic nitriles. |
| AID99235 | Compound was tested for the inhibition of LDH from a chloroquine-resistant strain (FCB/NC-1) of Plasmodium falciparum | 1986 | Journal of medicinal chemistry, Sep, Volume: 29, Issue:9 | Biologically active derivatives of gossypol: synthesis and antimalarial activities of peri-acylated gossylic nitriles. |
| AID1276044 | Competitive inhibition of human LDH1 in presence of NADH | 2016 | Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 | Recent Update on Human Lactate Dehydrogenase Enzyme 5 (hLDH5) Inhibitors: A Promising Approach for Cancer Chemotherapy. |
| AID159613 | Antimalarial activity against chloroquine-sensitive Plasmodium falciparum CDC/I/HB-3 | 1986 | Journal of medicinal chemistry, Sep, Volume: 29, Issue:9 | Biologically active derivatives of gossypol: synthesis and antimalarial activities of peri-acylated gossylic nitriles. |
| AID1276043 | Competitive inhibition of human LDH5 in presence of NADH | 2016 | Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 | Recent Update on Human Lactate Dehydrogenase Enzyme 5 (hLDH5) Inhibitors: A Promising Approach for Cancer Chemotherapy. |
| AID220721 | The compound was tested for inhibitory activity against aldose reductase from human placenta | 1991 | Journal of medicinal chemistry, Nov, Volume: 34, Issue:11 | Gossypol and derivatives: a new class of aldose reductase inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 3 (60.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.87) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (20.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (80.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||